Security
Tenon Medical, Inc. Warrant · TNONW
TNONWNASDAQWarrantCurrentCIK 1560293Updated Oct 23, 2026
TNONW price & chart
Loading TradingView…
NASDAQ:TNONW on TradingView ↗About the company
The Company was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. The Company currently offers two systems to treat a diseased sacroiliac joint (the “SI Joint”). The Company has developed The Catamaran™ SI Joint Fusion System (“The Catamaran System”) that offers a novel, less invasive approach to the SI Joint using a single, robust, titanium implant for treatment of the most common types of SI-Joint disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for The Catamaran System and is currently focused on the US market. The Company’s products are subject to ongoing FDA regulatory requirements, including requirements related to manufacturing, labeling, marketing, adverse event reporting and recordkeeping. Since the national launch of The Catamaran System in October 2022, the Company has been focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of …
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
EFFECT filing
424B3 filing
S-3 filing
Show 5 more recent filings
D filing
Items 06b
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other Events
Items 1.01, 3.02, 8.01, 9.01
4 filing
Other Events
Items 8.01, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 10,366,000Source | 13,039,000Source | 9,922,000Source | 11,114,000Source | 6,006,000Source | 12,838,000Source | 13,394,000Source | 8,020,000Source | 10,760,000Source | 9,843,000Source | 6,345,000Source | 11,089,000Source |
| Property, Plant and Equipment, NetUSD | 663,000Source | 906,000Source | 771,000Source | 842,000Source | 904,000Source | 901,000Source | 698,000Source | 993,000Source | 918,000Source | 752,000Source | 961,000Source | 793,000Source |
| GoodwillUSD | 2,407,000Source | — | 2,407,000Source | — | — | 2,407,000Source | — | — | 2,407,000Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 500,000Source | — | 455,000Source | — | — | 470,000Source | — | — | 485,000Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,442,000Source | 9,162,000Source | 1,677,000Source | 7,846,000Source | 1,968,000Source | 4,607,000Source | 10,311,000Source | 4,388,000Source | 3,756,000Source | 6,535,000Source | 2,428,000Source | 2,129,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,311,000Source | 876,000Source | 1,947,000Source | 770,000Source | 679,000Source | 1,969,000Source | 886,000Source | 571,000Source | 1,698,000Source | 863,000Source | 518,000Source | 228,000Source |
| Inventory, NetUSD | 1,364,000Source | 607,000Source | 783,000Source | 688,000Source | 609,000Source | 806,000Source | 607,000Source | 632,000Source | 1,054,000Source | 606,000Source | 554,000Source | 415,000Source |
| Assets, CurrentUSD | 6,545,000Source | 11,188,000Source | 4,807,000Source | 9,884,000Source | 4,087,000Source | 7,620,000Source | 11,990,000Source | 5,951,000Source | 6,768,000Source | 8,210,000Source | 3,889,000Source | 9,347,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 428,000Source | 543,000Source | 400,000Source | 580,000Source | 831,000Source | 238,000Source | 186,000Source | — | 260,000Source | 206,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 200,000Source | 463,000Source | 1,431,000Source | 268,000Source | 525,000Source | 1,389,000Source | 334,000Source | 586,000Source | 131,000Source | 399,000Source | 646,000Source | 873,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 5,568,000Source | 4,848,000Source | 11,665,000Source | 4,401,000Source | 5,174,000Source | 10,943,000Source | 4,018,000Source | 4,396,000Source | 5,720,000Source | 3,872,000Source | 5,567,000Source | 4,837,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 9,000Source | 3,000Source | — | 8,000Source | 4,000Source | 11,000Source | 8,000Source | 4,000Source | 11,000Source | 3,000Source | 3,000Source | 11,000Source |
| Additional Paid in CapitalUSD | 80,185,000Source | 70,095,000Source | 84,011,000Source | 78,084,000Source | 60,003,000Source | 83,588,000Source | 77,978,000Source | — | 83,257,000Source | 70,962,000Source | — | 45,833,000Source |
| Retained Earnings (Accumulated Deficit)USD | -78,470,000Source | -65,659,000Source | -88,828,000Source | -75,131,000Source | -62,475,000Source | -84,778,000Source | -72,362,000Source | -58,649,000Source | -81,302,000Source | -68,746,000Source | -55,073,000Source | -39,492,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | — | — | — | -46,000Source | -100,000Source |
| Stockholders' Equity Attributable to ParentUSD | 4,798,000Source | 8,191,000Source | -1,743,000Source | 6,713,000Source | 832,000Source | 1,895,000Source | 9,376,000Source | 3,624,000Source | 5,040,000Source | 5,971,000Source | 778,000Source | 6,252,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | — | — | — | — | 58,969,000Source | — | — | 55,894,000Source | — |
| Liabilities and EquityUSD | 10,366,000Source | 13,039,000Source | 9,922,000Source | 11,114,000Source | 6,006,000Source | 12,838,000Source | 13,394,000Source | 8,020,000Source | 10,760,000Source | 9,843,000Source | 6,345,000Source | 11,089,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,041,000Source | 3,178,000Source | 8,305,000Source | 2,563,000Source | 3,403,000Source | 7,405,000Source | 2,195,000Source | 2,262,000Source | 3,213,000Source | 1,869,000Source | 3,140,000Source | 2,530,000Source |
| Operating Lease, Liability, CurrentUSD | 216,000Source | 279,000Source | 215,000Source | 290,000Source | 271,000Source | 211,000Source | 295,000Source | 263,000Source | 141,000Source | 287,000Source | 256,000Source | 228,000Source |
| Accounts Payable, CurrentUSD | 625,000Source | 1,093,000Source | 628,000Source | 894,000Source | 1,111,000Source | 646,000Source | 496,000Source | 266,000Source | 845,000Source | 369,000Source | 433,000Source | 550,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 216,000Source | 1,131,000Source | — | 290,000Source | 1,186,000Source | 65,000Source | 360,000Source | — | 141,000Source | 428,000Source | 683,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,514,000Source | 908,000Source | 1,952,000Source | 1,108,000Source | 932,000Source | 1,774,000Source | 911,000Source | 941,000Source | 1,637,000Source | 910,000Source | 808,000Source | 717,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 6,441,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -18,917,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 88,000Source | 42,000Source | 262,000Source | 408,000Source | 199,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 331,000Source | 872,000Source | 1,691,000Source | 3,845,000Source | 4,145,000Source | 2,897,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 282,000Source | 23,000Source | 851,000Source | 386,000Source | 290,000Source | 152,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -248,000Source | -11,000Source | 387,000Source | 52,000Source | 139,000Source | 227,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -199,000Source | 127,000Source | 486,000Source | -64,000Source | -117,000Source | 72,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,960,000Source | -2,483,000Source | -10,745,000Source | -9,878,000Source | -12,183,000Source | -12,025,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -56,000Source | — | -1,023,000Source | -186,000Source | 6,142,000Source | -2,884,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 56,000Source | — | 273,000Source | 186,000Source | — | 847,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 3,867,000Source | 6,259,000Source | 8,989,000Source | 14,125,000Source | 6,302,000Source | 14,114,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 851,000Source | 3,776,000Source | -2,779,000Source | 4,107,000Source | 299,000Source | -788,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 3,442,000Source | 9,162,000Source | 1,677,000Source | 7,846,000Source | 4,607,000Source | 10,311,000Source | 3,756,000Source | 6,535,000Source | 2,428,000Source | 2,129,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | 46,000Source | 38,000Source | 7,000Source |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | 9,000Source | — | 15,000Source | 0Source | 15,000Source | 0Source | 24,000Source | — | — | — |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 58,000Source | 910,000Source | 412,000Source | 417,000Source | 331,000Source | 872,000Source | 1,691,000Source | 3,845,000Source | 4,145,000Source | 2,897,000Source |
| DepreciationUSD | — | — | 68,000Source | 105,000Source | 45,000Source | 48,000Source | 73,000Source | 42,000Source | 238,000Source | 395,000Source | — | 78,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | 53,000Source | 31,000Source | 24,000Source | 88,000Source | 25,000Source | 61,000Source | 236,000Source | 183,000Source | 167,000Source | 180,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | -77,000Source |
| General and Administrative ExpenseUSD | — | — | 2,199,000Source | 1,764,000Source | 1,531,000Source | 1,480,000Source | 1,705,000Source | 1,662,000Source | 6,975,000Source | 7,765,000Source | 7,027,000Source | 7,423,000Source |
| GoodwillUSD | — | — | 2,407,000Source | — | 2,407,000Source | — | 2,407,000Source | — | 2,407,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -12,556,000Source | -13,673,000Source | -15,581,000Source | — |
| InterestExpenseNonoperatingUSD | — | — | — | — | 852,000Source | — | 176,000Source | — | — | 34,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,339,000Source | -3,184,000Source | -4,050,000Source | -2,769,000Source | -3,476,000Source | -3,616,000Source | -12,556,000Source | -13,673,000Source | -15,581,000Source | -18,917,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Nonoperating Income (Expense)USD | — | — | 53,000Source | 31,000Source | -696,000Source | 88,000Source | -196,000Source | 61,000Source | 236,000Source | 93,000Source | 146,000Source | -192,000Source |
| Operating ExpensesUSD | — | — | 4,165,000Source | 3,633,000Source | 4,168,000Source | 3,102,000Source | 4,225,000Source | 4,000,000Source | 15,150,000Source | 15,477,000Source | 16,968,000Source | 18,084,000Source |
| Other Depreciation and AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 193,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | — | — | 132,000Source | — | -45,000Source | — | — | -56,000Source | — | — |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | 509,000Source | — |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 10,116,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 2,106,000Source | 4,808,000Source | 14,139,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 16,000Source |
| Derivative, Gain (Loss) on Derivative, Net | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,173,000Source | 887,000Source | 1,279,000Source | 564,000Source | 1,379,000Source | 726,000Source | 3,944,000Source | 3,277,000Source | 2,928,000Source | 691,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -3,392,000Source | -3,215,000Source | -3,354,000Source | -2,857,000Source | -3,280,000Source | -3,677,000Source | -12,792,000Source | -13,766,000Source | -15,727,000Source | -18,725,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | 132,000Source | — | -45,000Source | — | — | -56,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -18,916,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,339,000Source | -3,184,000Source | -4,050,000Source | -2,769,000Source | -3,476,000Source | -3,616,000Source | -12,556,000Source | -13,673,000Source | -15,581,000Source | -18,917,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.4Source | -3.63Source | -12.35Source | -12.76Source | -0.31Source | -1.01Source | -1.7Source | -11.26Source | -8.59Source | -2.36Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.4Source | -3.63Source | -12.35Source | -12.76Source | 0.31Source | 1.01Source | -1.7Source | -11.26Source | -8.59Source | -2.36Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 8,250Source | 877Source | 328Source | 217Source | 11,268Source | 3,597Source | 7,384Source | 1,214Source | 1,814Source | 8,008Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 8,250Source | 877Source | 328Source | 217Source | 11,268Source | 3,597Source | 7,384Source | 1,214Source | 1,814Source | 8,008Source |
| Interest Expense (non-operating)USD | — | — | — | — | 852,000Source | — | 176,000Source | — | — | 34,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | 1,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 88,000Source | 42,000Source | 262,000Source | 408,000Source | — | — |
| Gain (Loss) on InvestmentsUSD | — | — | 53,000Source | 31,000Source | 24,000Source | 88,000Source | 25,000Source | 61,000Source | 236,000Source | 183,000Source | 167,000Source | 180,000Source |
| General and Administrative ExpenseUSD | — | — | 2,199,000Source | 1,764,000Source | 1,531,000Source | 1,480,000Source | 1,705,000Source | 1,662,000Source | 6,975,000Source | 7,765,000Source | 7,027,000Source | 7,423,000Source |
| Gross ProfitUSD | — | — | 773,000Source | 418,000Source | 814,000Source | 245,000Source | 945,000Source | 323,000Source | 2,358,000Source | 1,711,000Source | 1,241,000Source | -641,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -12,556,000Source | -13,673,000Source | -15,570,000Source | -18,886,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -12,556,000Source | -13,673,000Source | -15,581,000Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 21,000Source | — |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 354,000Source |
| Nonoperating Income (Expense)USD | — | — | 53,000Source | 31,000Source | -696,000Source | 88,000Source | -196,000Source | 61,000Source | 236,000Source | 93,000Source | 146,000Source | -192,000Source |
| Operating ExpensesUSD | — | — | 4,165,000Source | 3,633,000Source | 4,168,000Source | 3,102,000Source | 4,225,000Source | 4,000,000Source | 15,150,000Source | 15,477,000Source | 16,968,000Source | 18,084,000Source |
| Research and Development ExpenseUSD | — | — | 428,000Source | 657,000Source | 768,000Source | 503,000Source | 662,000Source | 691,000Source | 2,149,000Source | 2,603,000Source | 3,163,000Source | 2,828,000Source |
| Selling and Marketing ExpenseUSD | — | — | 1,538,000Source | 1,212,000Source | 1,869,000Source | 1,119,000Source | 1,858,000Source | 1,647,000Source | 6,026,000Source | 5,109,000Source | 6,778,000Source | 7,833,000Source |
| Other Expenses | — | — | — | — | — | — | — | —Source | — | — | — | — |
Offerings
Registration 333-299284
Registration 333-292032
Registration 333-298245
Registration 333-296952
- Gross proceeds
- 4200000.0
- Net proceeds
- 3927000.0
- Deal price
- 0.38
- Shares
- 11052632
- Offering price
- $0.3800
- Ticker
- TNON
Registration 333-297142
Registration 333-286387
Filing attachments
ea030925401ex4-1.htm · 8-K · 2026-10-22
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗ea030566801ex4-1.htm · 8-K · 2026-09-16
EX-4.1 2 ea030566801ex4-1.htm FORM OF SERIES B WARRANT Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT…
Read attachment ↗ea030566801ex99-1.htm · 8-K · 2026-09-16
EX-99.1 5 ea030566801ex99-1.htm PRESS RELEASE, DATED SEPTEMBER 11, 2026 Exhibit 99.1 Tenon Medical Announces Warrant Inducement for Aggregate Gross Proceeds of Approximately $2,872,338 LOS GATOS, CA / ACCESS Newswire / September 11, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) (“Tenon” or the “Company”), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders announced today it has entered into warrant exercise agreements with an institutional i…
Read attachment ↗ea030566801ex99-2.htm · 8-K · 2026-09-16
EX-99.2 6 ea030566801ex99-2.htm PRESS RELEASE, DATED SEPTEMBER 15, 2026 Exhibit 99.2 Tenon Medical Announces Closing of Warrant Inducement Offering for Aggregate Gross Proceeds of Approximately $2,872,338 LOS GATOS, CA / ACCESS Newswire / September 14, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) (“Tenon” or the “Company”), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders announced today it has closed its previously announced warrant indu…
Read attachment ↗ea030488401ex99-1.htm · 8-K · 2026-09-09
EX-99.1 2 ea030488401ex99-1.htm PRESS RELEASE OF TENON MEDICAL, INC., DATED SEPTEMBER 9, 2026 Exhibit 99.1 Tenon Medical Announces Early Repayment of its Convertible Notes ~ Company Takes Proactive Step to Strengthen Balance Sheet and Maintain Flexibility to Execute on Continued Business Momentum ~ Los Gatos, CA, September 9, 2026 - Tenon Medical, Inc. (NASDAQ: TNON) (“Tenon” or the “Company”), a medical device company dedicated to transforming care for patients with certain sacro-pelvic …
Read attachment ↗ea030388301ex4-1.htm · 8-K · 2026-08-31
EX-4.1 3 ea030388301ex4-1.htm FORM OF PRE-FUNDED WARRANT Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES A…
Read attachment ↗